{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:39:57Z","timestamp":1795041597136,"version":"4.10.2"},"reference-count":34,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Molecular failure in NPM1-mutated acute myeloid leukemia (AML) inevitably progresses to frank relapse if untreated. Recently published small case series show that venetoclax combined with low-dose cytarabine or azacitidine can reduce or eliminate measurable residual disease (MRD). Here, we report on an international multicenter cohort of 79 patients treated for molecular failure with venetoclax combinations and report an overall molecular response (\u22651-log reduction in MRD) in 66 patients (84%) and MRD negativity in 56 (71%). Eighteen of 79 patients (23%) required hospitalization, and no deaths were reported during treatment. Forty-one patients were bridged to allogeneic transplant with no further therapy, and 25 of 41 were MRD negative assessed by reverse transcription quantitative polymerase chain reaction before transplant. Overall survival (OS) for the whole cohort at 2 years was 67%, event-free survival (EFS) was 45%, and in responding patients, there was no difference in survival in those who received a transplant using time-dependent analysis. Presence of FLT3-ITD mutation was associated with a lower response rate (64 vs 91%; P\u00a0&amp;lt; .01), worse OS (hazard ratio [HR], 2.50; 95% confidence interval [CI], 1.06-5.86; P\u00a0= .036), and EFS (HR, 1.87; 95%\u00a0CI, 1.06-3.28; P\u00a0= .03). Eighteen of 35 patients who did not undergo transplant became MRD negative and stopped treatment after a median of 10\u00a0months, with 2-year molecular relapse free survival of 62% from the end of treatment. Venetoclax\u2013based low intensive chemotherapy is a potentially effective treatment for molecular relapse in NPM1-mutated AML, either as a bridge to transplant or as definitive therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011106","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T21:34:25Z","timestamp":1701466465000},"page":"343-352","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Venetoclax\u2013based low intensity therapy in molecular failure of <i>NPM1<\/i>-mutated AML"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-398X","authenticated-orcid":false,"given":"Carlos","family":"Jimenez-Chillon","sequence":"first","affiliation":[{"name":"1Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"},{"name":"2Department of Medical & Molecular Genetics, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-3576","authenticated-orcid":false,"given":"Jad","family":"Othman","sequence":"additional","affiliation":[{"name":"2Department of Medical & Molecular Genetics, King\u2019s College London, London, United Kingdom"},{"name":"3Guy\u2019s and St Thomas Hospital, London, United Kingdom"},{"name":"4Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taussig","sequence":"additional","affiliation":[{"name":"5Department of Haematology, Royal Marsden Hospital, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-4305","authenticated-orcid":false,"given":"Carlos","family":"Jimenez-Vicente","sequence":"additional","affiliation":[{"name":"6Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-5356","authenticated-orcid":false,"given":"Alexandra","family":"Martinez-Roca","sequence":"additional","affiliation":[{"name":"6Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"7Hematology Department, Hospital Cl\u00ednic Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-4343","authenticated-orcid":false,"given":"Ing Soo","family":"Tiong","sequence":"additional","affiliation":[{"name":"8Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"9Alfred Hospital and Monash University, Melbourne, VIC, Australia"},{"name":"10Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-8838","authenticated-orcid":false,"given":"Manish","family":"Jain","sequence":"additional","affiliation":[{"name":"11Department of Haematology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Aries","sequence":"additional","affiliation":[{"name":"12Department of Haemato-Oncology, St Bartholomew\u2019s Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Cakmak","sequence":"additional","affiliation":[{"name":"12Department of Haemato-Oncology, St Bartholomew\u2019s Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-4441","authenticated-orcid":false,"given":"Steven","family":"Knapper","sequence":"additional","affiliation":[{"name":"13Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6753-7051","authenticated-orcid":false,"given":"Daniel Tuyet","family":"Kristensen","sequence":"additional","affiliation":[{"name":"14Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhya","family":"Murthy","sequence":"additional","affiliation":[{"name":"15Department of Haematology, University Hospitals of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Zacharoula","family":"Galani","sequence":"additional","affiliation":[{"name":"16Department of Haematology, Dartford & Gravesham NHS Trust, Dartford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kallmeyer","sequence":"additional","affiliation":[{"name":"17Department of Haematology, Lincoln County Hospital, Lincoln, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Ngu","sequence":"additional","affiliation":[{"name":"18Department of Haematology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Veale","sequence":"additional","affiliation":[{"name":"18Department of Haematology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bolam","sequence":"additional","affiliation":[{"name":"19Department of Haematology, Taunton and Somerset NHS Foundation Trust, Taunton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Orfali","sequence":"additional","affiliation":[{"name":"20Department of Haematology, St. James's Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4905-6860","authenticated-orcid":false,"given":"Anne","family":"Parker","sequence":"additional","affiliation":[{"name":"21Department of Haematology, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Manson","sequence":"additional","affiliation":[{"name":"21Department of Haematology, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Parker","sequence":"additional","affiliation":[{"name":"22Department of Haematology, Northampton General Hospital, Northampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Erblich","sequence":"additional","affiliation":[{"name":"23Department of Haematology, The London Clinic, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Richardson","sequence":"additional","affiliation":[{"name":"24Department of Haematology, University Hospital Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Mokretar","sequence":"additional","affiliation":[{"name":"25Synnovis, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8256-9350","authenticated-orcid":false,"given":"Nicola","family":"Potter","sequence":"additional","affiliation":[{"name":"2Department of Medical & Molecular Genetics, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik Malthe","family":"Overgaard","sequence":"additional","affiliation":[{"name":"26Department of Haematology, Rigshospitalet, Copenhagen, Denmark"},{"name":"27Department of Haematology, National Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-5432","authenticated-orcid":false,"given":"Anne Stidsholt","family":"Roug","sequence":"additional","affiliation":[{"name":"14Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"},{"name":"28Department of Hematology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"8Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[{"name":"7Hematology Department, Hospital Cl\u00ednic Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"J\u00e4dersten","sequence":"additional","affiliation":[{"name":"29Department of Medicine, Center for Haematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"30Department of Haematology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Russell","sequence":"additional","affiliation":[{"name":"3Guy\u2019s and St Thomas Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5296","authenticated-orcid":false,"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"2Department of Medical & Molecular Genetics, King\u2019s College London, London, United Kingdom"},{"name":"3Guy\u2019s and St Thomas Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"issue":"1","key":"2024012215511430300_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2024012215511430300_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia French association group","volume":"35","author":"Balsat","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2024012215511430300_bib3","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2024012215511430300_bib4","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"issue":"26","key":"2024012215511430300_bib5","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2024012215511430300_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2024012215511430300_bib7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2024012215511430300_bib8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024012215511430300_bib9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2024012215511430300_bib10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"2024012215511430300_bib11","doi-asserted-by":"crossref","first-page":"10774","DOI":"10.1038\/s41598-023-38037-5","article-title":"Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience","volume":"13","author":"J\u00e4ger","year":"2023","journal-title":"Sci Rep"},{"issue":"12","key":"2024012215511430300_bib12","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024012215511430300_bib13","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"2024012215511430300_bib14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.18887","article-title":"A\u00a0venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure","volume":"202","author":"Sartor","year":"2023","journal-title":"Br J Haematol"},{"issue":"20","key":"2024012215511430300_bib15","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2024012215511430300_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2024012215511430300_bib17","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1182\/bloodadvances.2021005455","article-title":"Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia","volume":"5","author":"Tiong","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2024012215511430300_bib18","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"issue":"25","key":"2024012215511430300_bib19","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024012215511430300_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjh.16857","article-title":"Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease","volume":"191","author":"Bataller","year":"2020","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2024012215511430300_bib21","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1182\/blood-2022-163041","article-title":"A\u00a0prospective phase 2 study of venetoclax and low dose ara-C (VALDAC) to target rising molecular measurable residual disease and early relapse in acute myeloid leukemia","volume":"140","author":"Tiong","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2024012215511430300_bib22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2024012215511430300_bib23","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2024012215511430300_bib24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","article-title":"Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann Hematol"},{"issue":"15","key":"2024012215511430300_bib25","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024012215511430300_bib26","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024012215511430300_bib27","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024012215511430300_bib28","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2024012215511430300_bib29","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am J Hematol"},{"issue":"13","key":"2024012215511430300_bib30","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2024012215511430300_bib31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"issue":"7","key":"2024012215511430300_bib32","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1038\/bcj.2016.46","article-title":"Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"6","author":"Kayser","year":"2016","journal-title":"Blood Cancer J"},{"issue":"13","key":"2024012215511430300_bib33","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"2024012215511430300_bib34","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/343\/2210466\/blooda_adv-2023-011106-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/343\/2210466\/blooda_adv-2023-011106-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T15:51:34Z","timestamp":1705938694000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/2\/343\/506382\/Venetoclax-based-low-intensity-therapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011106","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]}}}